AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01537042
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal.
Trial: NCT01194232
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
Trial: NCT01969773
Drug: Botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
Trial: NCT01969773
Drug: Normal saline instillation
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
Trial: NCT02473627
Drug: midazolam hydrochloride
RxNorm normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5mg oromucosal liquid
Trial: NCT02473627
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg gastro-resistant capsule
Trial: NCT02473627
Drug: Pioglitazone hydrochloride
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg tablet
Trial: NCT02473627
Drug: Tolbutamide
RxNorm normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg tablet
Trial: NCT00413582
Drug: Epidural Analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
Trial: NCT00314327
Drug: long-acting injectable risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
Trial: NCT00019773
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01842230
Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~* over the period I \& II(cross-over)
Trial: NCT01842230
Drug: Telmisartan 80mg and S-amlodipine 5mg
RxNorm normalized name: S-amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* over the period I \& II(cross-over)
Trial: NCT01804946
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Safety and Efficiency in treatment of Influenza
Trial: NCT00315458
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch applied for 7-day wear.
Trial: NCT00450879
Drug: Pazopanib Hydrochloride
RxNorm normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02433184
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
Trial: NCT02433184
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
Trial: NCT02433184
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
Trial: NCT02433184
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
Trial: NCT02045264
Drug: Icatibant (30 mg)
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
Trial: NCT02382575
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
Trial: NCT02382575
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
Trial: NCT00147875
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00147875
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00147875
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00546533
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00722137
Drug: Rituximab 375 mg/m^2
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
Trial: NCT00722137
Drug: Prednisone 100 mg/m^2
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
Trial: NCT00722137
Drug: Vincristine 1.4 mg/m^2
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
Trial: NCT02822937
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
Trial: NCT02822937
Drug: Triazolam
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
Trial: NCT02573051
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
Trial: NCT02573051
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
Trial: NCT04368546
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01367886
Drug: fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg. tablet by mouth daily for six weeks
Trial: NCT00574704
Drug: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
RxNorm normalized name: European house dust mite allergenic extract
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections at 6 visits
Trial: NCT00574704
Drug: House dust mite allergen extract in combination with CYT003-QbG10-placebo
RxNorm normalized name: European house dust mite allergenic extract
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections at 6 visits
Trial: NCT00574704
Drug: CYT003-AllQbG10 in combination with house dust mite allergen extract placebo
RxNorm normalized name: European house dust mite allergenic extract
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections at 6 visits
Trial: NCT00574704
Drug: CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo
RxNorm normalized name: European house dust mite allergenic extract
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections at 6 visits
Trial: NCT00985504
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
Trial: NCT00985504
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
Trial: NCT00004208
Drug: ATG + CSA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
Trial: NCT00400023
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.~During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks.
Trial: NCT00400023
Drug: FT
RxNorm normalized name: FTA
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
Trial: NCT02872714
Drug: pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
Trial: NCT02872714
Drug: pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemigatinib once a day by mouth continuously.
Trial: NCT02913118
Drug: Andrographolid Sulfonate Injection (AS Injection)
RxNorm normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02913118
Drug: Cephalosporin
RxNorm normalized name: Cephalosporin
DrugBank: Cephalosporin analog (DB02136)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02913118
Drug: Amoxicillin-clavulantic acid
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04020666
Drug: Urinary Kallidinogenase
RxNorm normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00733421
Drug: tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg twice daily
Trial: NCT00251238
Drug: Ginkgo biloba extract EGb 761
RxNorm normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily Ginkgo biloba extract EGb 761
Trial: NCT04344483
Drug: 2% Lidocaine and 1:100,000 Adrenaline
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.
Trial: NCT01666951
Drug: LCP-Tacro tablets
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus
Trial: NCT01666951
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus
Trial: NCT03040713
Drug: Flortaucipir F18
RxNorm normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose
Trial: NCT00900874
Drug: salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two puffs (100 microgram each of salbutamol) by MDI and spacer
Trial: NCT00181727
Drug: divalproex sodium extended release
RxNorm normalized name: divalproex sodium Extended Release Oral Tablet
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00975182
Drug: GDC-0941
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT00975182
Drug: erlotinib HCl
RxNorm normalized name: erlotinib HCl
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT00964574
Drug: INSULIN GLULISINE (HMR1964)
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day
Trial: NCT00964574
Drug: INSULIN GLARGINE
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening
Trial: NCT01922037
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
Trial: NCT00261209
Drug: Collagenase
RxNorm normalized name: Collagenase
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collagenase injection into adhesion restricting tendon gliding
Trial: NCT00261209
Drug: Collagenase injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of collagenase into adhesion restricting tendon gliding
Trial: NCT00961675
Drug: FST201 (dexamethasone 0.1% with povidone-iodine 1%)
RxNorm normalized name: povidone-iodine 0.1 MG/MG
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 gtt BID (twice a day)
Trial: NCT00961675
Drug: Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 gtt BID (twice a day)
Trial: NCT00191581
Drug: Humalog Mix 50
RxNorm normalized name: HumaLOG Mix 50/50
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04158167
Drug: oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
Trial: NCT02157935
Drug: Symbicort
RxNorm normalized name: Symbicort
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
Trial: NCT02157935
Drug: Formoterol turbohaler
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
Trial: NCT01120184
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
Trial: NCT01120184
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2 intravenously weekly for a minimum of 18 weeks
Trial: NCT01120184
Drug: pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
Trial: NCT01120184
Drug: pertuzumab-placebo
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
Trial: NCT01120184
Drug: trastuzumab [Herceptin]
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trastuzumab \[Herceptin\] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
Trial: NCT01120184
Drug: trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3.6 mg/kg intravenously every 3 weeks
Trial: NCT02596971
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
Trial: NCT02596971
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
Trial: NCT02596971
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
Trial: NCT02596971
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m\^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).